 |
Activity Overview | |
| CME/CE Information | ||
| Method of Instruction | ||
| Faculty Information | ||
| Monograph (PDF* 1.7 mb download) | ||
| References | ||
| Abbreviations | ||
| Permissions List | ||
| Post-Test/Evaluation |
Presentations
Clinical Outcomes in CKD Stage 5: The Impact of Mineral and Bone Disorders
David Goldsmith, MA, MB, FRCP (Chair)
Benefits of Vitamin D Therapy on Mortality
Ellie Kelepouris, MD
Can Your Choice of Phosphate Binders Change Dialysis Patient Outcomes?
Paolo Raggi, MD, FACP, FACC
Activity Overview
Chronic Kidney Disease (CKD) is a growing global epidemic with adverse morbidity and compromised long-term outcomes. Mineral and bone disorders associated with CKD contribute to increased hospitalization, increased cardiovascular events, and increased mortality among affected patients.
In the US, the population of patients with CKD stage 5 is expected to reach 2.2 million by the year 2030 and improving outcomes in CKD stage 5 has become a clinical imperative. Recent evidence indicates that treatment of patients with CKD stage 5 with active vitamin D hormone therapy and with phosphate binders can improve survival outcomes.
This monograph will review data regarding the benefits of vitamin D therapy and the appropriate use of phosphate binders in patients with CKD stage 5 on dialysis.
CME/CE Information
Audience
This activity is designed for:
- Physicians
- Physician Assistants
- Nurses
- Nurse Practitioners
- Dietitians
- Pharmacists
- Dialysis Technicians
Learning Objectives
Upon completion of this activity participants should be able to:
- Describe the rationale for treating bone and mineral metabolism in CKD stage 5 patients, and the advantages and disadvantages of specific therapeutic options
- Discuss data on vitamin D therapy and mortality in CKD patients
- Discuss data on phosphate binders and outcomes in CKD patients
Method of Instruction
Participants should read the activity overview, learning objectives, faculty disclosure and review the online monograph in its entirety. After reviewing the online monograph, participants should complete the post-test and the activity evaluation. The estimated time for program is 1.5 hours.
If you receive a passing score for the post-test, you will be able to download and print a certificate. A minimum score of 75% is required for certification. If you do not pass the test, you may take the test again.
Release Date: August 3, 2007
Accreditation
Physician
The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistant
AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit(s) TM for the PRA from organizations accredited by ACCME.
Nurse and Dialysis Technician
The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned code 6EXQ7J-PRV-O6.
This educational activity is approved for 1.5 contact hours.
Nurse Practitioner
This program has been approved for 1.2 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0706276.
Dietitian
The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.
Pharmacist
The University of Missouri-Kansas City, School of Pharmacy, is approved by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. The ACPE universal program number assigned to this educational offering is 034-999-07-032-H01.
This program is accredited by the University of Missouri-Kansas City for 0.1 CEU (1.0 contact hour). All participants who successfully complete the program will be mailed the continuing education credit slip within three weeks.
Declaration of Disclosure
It is the policy of the National Kidney Foundation to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Faculty participating in this activity are required to disclose to the audience any relationship they may have with the commercial supporters of this activity or with any other commercial organizations whose products or devices may be mentioned in their presentations. If, on the basis of information disclosed a conflict exists, resolution will be achieved based on established policy by the NKF.
Unlabeled/Investigational Use
During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
Disclaimer
The faculty, National Kidney Foundation, and Genzyme Corporation do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.
Faculty
David Goldsmith, MA, MB, FRCP (Chair)
Consultant Nephrologist
Guy’s and St Thomas’ Hospital, Renal Unit
London, United Kingdom
Ellie Kelepouris, MD
Deputy Chief
Professor of Medicine
Department of Medicine, Section of Nephrology and Kidney Transplantation
Temple University School of Medicine
Philadelphia, Pennsylvania
Paolo Raggi, MD, FACP, FACC
Professor of Medicine and Radiology
Emory University School of Medicine
Atlanta, Georgia
Faculty Disclosures
David Goldsmith, MA, MB, FRCP
Has indicated he has nothing to disclose.
Ellie Kelepouris, MD
Consultant Scientific Advisor: Watson Pharmaceuticals
Speaker’s Bureau: Watson Pharmaceuticals, Genzyme Corporation
Paolo Raggi, MD, FACP, FACC
Grant Research Support: Genzyme Corporation, Amgen, Inc.
Speaker’s Bureau: Genzyme Corporation
Faculty Biographies
David Goldsmith, MA, MB, FRCP
David Goldsmith MA, MB, FRCP is a consultant nephrologist at Guy’s Hospital in London, United Kingdom. He is also an Associate Professor of Nephrology having senior roles in the UK Renal Association and European Renal Association. His research interests are in the area of cardiovascular disease in chronic kidney disease.
Ellie Kelepouris, MD
Ellie Kelepouris, MD is Deputy Chief and Professor of Medicine in the Department of Medicine, Section of Nephrology and Kidney Transplantation at the Temple University School of Medicine in Philadelphia, Pennsylvania. Dr. Kelepouris received her medical degree the University of Athens School of Medicine, Athens Greece.
Dr. Kelepouris is an active researcher, with clinical interests in the areas of adult polycystic kidney disease, nephrolithiasis, cardiovascular disease in renal failure, hypertension, and mineral metabolism and bone disease. Her research interests include the study of vitamin D metabolism in renal failure, mechanism of hypertension, risk factors for chronic kidney disease, and epithelial ion channel regulation in kidney disease.
Paolo Raggi, MD, FACP, FACC
Paolo Raggi, MD, FACP, FACC, recently joined Emory University as Professor of Medicine-Cardiology and Professor of Radiology. Previously, he was Assistant Professor of Medicine at Tulane University in New Orleans, where he directed the training program in adult cardiology. Dr. Raggi received his doctor of medicine and surgery degree summa cum laude from the University of Bologna Medical School in Bologna Italy.
Dr. Raggi is actively involved in several clinical activities at the Division of Cardiology at Emory University that include echocardiology and nuclear cardiology test interpretation, performance of diagnostic cardiac catheterization, rounding on patient wards and new patient visits in the outpatient clinic area. Among his current research interests are surrogate markers of atherosclerosis, preventative cardiology, follow-up of progression of atherosclerosis by non-invasive imaging and cardiovascular disease in patients affected by chronic kidney disease stage 5.
Go to monograph (PDF* 1.7 mb download)
Post Test/Evaluation
Physician
Physician Assistant
Nurse and Technician
Nurse Practitioner
Dietitian
Pharmacist
Other
